» Articles » PMID: 27334779

Short-, Intermediate-, and Long-Term Changes in Basophil Reactivity Induced by Venom Immunotherapy

Overview
Date 2016 Jun 24
PMID 27334779
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The basophil activation test (BAT) has been used to monitor venom immunotherapy (VIT) due to its high specificity. A previous study has reported a good correlation between a significant decrease in basophil activation during 5 years of VIT and clinical protection assessed by sting challenge. The following prospective study was performed to examine changes in basophil reactivity over a complete VIT period of 5 years.

Methods: BAT in a dose-response curve was studied prospectively in 10 hymenoptera venom-allergic patients over 5 years of VIT. BAT was performed at the time of diagnosis, 1 month after finishing the VIT build-up phase, and 3, 6, 12, 24, and 60 months after beginning treatment. The repeated measures ANOVA was applied to evaluate basophil activation changes throughout VIT. A cross-sectional study was also performed in 6 patients who received treatment for more than 3 years, and in another 12 patients who followed immunotherapy for at least 5 years.

Results: An early activation decrease was observed during the first 3 months of treatment, compared to pre-treatment values. This activation decrease was not maintained 6 to 18 months after treatment, but was observed again after 2 years of treatment, and maintained until the completion of the 5-year immunotherapy period. In cross-sectional analysis, the 6 patients who received treatment for 3 years, and 9 of the 12 patients who received treatment for 5 years, had negative BAT results. Three patients in this last group had positive BAT results and 2 patients had systemic reactions after field stings.

Conclusions: BAT appears to be an optimal non-invasive test for close monitoring of VIT.

Citing Articles

Cellular and Humoral Response After Induction of Protection and After Finishing Venom Immunotherapy.

Luzar A, Rijavec M, Kosnik M, Bidovec-Stojkovic U, Debeljak J, Zidarn M Biomolecules. 2025; 14(12.

PMID: 39766201 PMC: 11673861. DOI: 10.3390/biom14121494.


Basophil activation test in Hymenoptera venom allergy.

Eberlein B, Brockow K, Darsow U, Biedermann T, Blank S Allergol Select. 2024; 8:293-298.

PMID: 39211355 PMC: 11361271. DOI: 10.5414/ALX02522E.


Natural and Induced Tolerance to Hymenoptera Venom: A Single Mechanism?.

Navas A, Ruiz-Leon B, Serrano P, Marti M, Espinazo M, Blanco N Toxins (Basel). 2022; 14(7).

PMID: 35878164 PMC: 9320229. DOI: 10.3390/toxins14070426.


Venom Immunotherapy: Immune Mechanisms of Induced Protection and Tolerance.

Luzar A, Korosec P, Kosnik M, Zidarn M, Rijavec M Cells. 2021; 10(7).

PMID: 34206562 PMC: 8306808. DOI: 10.3390/cells10071575.


Association between Venom Immunotherapy and Changes in Serum Protein-Peptide Patterns.

Matysiak J, Matuszewska E, Kowalski M, Kosinski S, Smorawska-Sabanty E, Matysiak J Vaccines (Basel). 2021; 9(3).

PMID: 33809001 PMC: 8001044. DOI: 10.3390/vaccines9030249.


References
1.
Mikkelsen S, Bibby B, Dolberg M, Dahl R, Hoffmann H . Basophil sensitivity through CD63 or CD203c is a functional measure for specific immunotherapy. Clin Mol Allergy. 2010; 8(1):2. PMC: 2831812. DOI: 10.1186/1476-7961-8-2. View

2.
Sainte-Laudy J, VALLON C, Guerin J . [Analysis of membrane expression of the CD63 human basophil activation marker. Applications to allergologic diagnosis]. Allerg Immunol (Paris). 1994; 26(6):211-4. View

3.
Rodriguez-Trabado A, Camara-Hijon C, Ramos-Cantarino A, Porcel-Carreno S, Jimenez-Timon S, Pereira-Navarro G . Basophil activation test for the in vitro diagnosis of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Proc. 2008; 29(3):241-9. DOI: 10.2500/aap.2008.29.3114. View

4.
Graft D . Discontinuing venom immunotherapy. J Allergy Clin Immunol. 1997; 99(2):271. DOI: 10.1016/s0091-6749(97)70118-0. View

5.
Korosec P, Erzen R, Silar M, Bajrovic N, Kopac P, Kosnik M . Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin Exp Allergy. 2009; 39(11):1730-7. DOI: 10.1111/j.1365-2222.2009.03347.x. View